About Us

Daniel Levin, MA, PhD, CChem, FRSC
President; Norac Pharma

Danny Levin is President of Norac Pharma. He manages all aspects of the business whilst maintaining particular interest in process research and development and safe scale up with a view to new product manufacturing. Danny has over 30 years of industrial process R&D and manufacturing experience in Europe, Canada, USA and India, working with ICI, Zeneca, AstraZeneca, Avecia, Torcan and Piramal Healthcare, before moving to Norac Pharma in 2007.

Danny's academic qualifications comprise 1st class honors Bachelors, Masters and PhD degrees from Cambridge University in the UK. He is widely published in both chemistry literature and patent applications, with over 100 citations to his work and has been recognized with Fellowship of the UK Royal Society of Chemistry. He has also taught synthetic chemistry as Adjunct Professor at Toronto's York University.

Danny brings to Norac Pharma a breadth of experience in complex pharmaceutical chemistry process R&D based on sound mechanistic and kinetic understanding. He has demonstrated manufacturing achievements across a wide range of synthetic targets and scales of manufacture. Danny has been responsible for defining process chemistry and supplying API across all phases of pharma development, from discovery through preclinical, clinical trials, process validation, commercial optimization and life cycle extension. This has been done with strong attention to quality, regulatory and process safety (including successful defense to FDA Advisory Committee and authorship of a 70 page chapter on process safety for the American Chemical Society). Danny's wide range of experience allows him and his colleagues to tailor Norac Pharma process R&D offering to best suit client needs, well matched to drug development phase.

Please don’t hesitate to contact us to discuss your drug development needs in strictest confidence and without obligation.